In T2D patients with DPP-4-high RCC tumors, treatment with DPP-4i improved TKI responses, suggesting DPP-4 inhibition could be a potential strategy to overcome TKI resistance [25]. This evidence concerns the gene DPP4 and renal cell carcinoma.